Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Veracyte (VCYT) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Veracyte (VCYT) over the last 14 years, with Q3 2025 value amounting to 17.4%.

  • Veracyte's EBITDA Margin rose 70300.0% to 17.4% in Q3 2025 from the same period last year, while for Sep 2025 it was 5.0%, marking a year-over-year increase of 105300.0%. This contributed to the annual value of 3.62% for FY2024, which is 273800.0% up from last year.
  • Per Veracyte's latest filing, its EBITDA Margin stood at 17.4% for Q3 2025, which was up 70300.0% from 4.05% recorded in Q2 2025.
  • Veracyte's EBITDA Margin's 5-year high stood at 17.4% during Q3 2025, with a 5-year trough of 114.07% in Q1 2021.
  • In the last 5 years, Veracyte's EBITDA Margin had a median value of 12.74% in 2023 and averaged 15.64%.
  • In the last 5 years, Veracyte's EBITDA Margin tumbled by -764300bps in 2021 and then soared by 915800bps in 2022.
  • Quarter analysis of 5 years shows Veracyte's EBITDA Margin stood at 18.32% in 2021, then surged by 63bps to 6.75% in 2022, then crashed by -436bps to 36.16% in 2023, then surged by 110bps to 3.52% in 2024, then surged by 394bps to 17.4% in 2025.
  • Its EBITDA Margin stands at 17.4% for Q3 2025, versus 4.05% for Q2 2025 and 2.54% for Q1 2025.